Key facts
- Mabwell's 9MW5211 received IND clearance from China's NMPA.
- The drug is being developed for inflammatory bowel disease (IBD).
- Mabwell is a biopharmaceutical company with a fully integrated industry chain.
Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced on June 4, 2026, that its independently developed innovative antibody drug 9MW5211 has received approval from China's National Medical Products Administration (NMPA). The drug is intended for the treatment of inflammatory bowel disease (IBD). Mabwell is listed on the Shanghai Stock Exchange (688062.SH) and the Hong Kong Stock Exchange (02493.HK).